Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 3 3Phase 2/3 2Phase 1/2 2Phase NA 1

Status

Unknown 2Not yet recruiting 2Terminated 1Recruiting 1

Sponsor Class

OTHER 5INDUSTRY 1

Study Type

Interventional 6

Sponsor

Cancer Type

Thoracic 6Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 275Lung Neoplasms 106Adenocarcinoma of Lung 27Mesothelioma, Malignant 22Neoplasms 19Neoplasm Metastasis 18Breast Neoplasms 13Brain Neoplasms 13Mesothelioma 10Head and Neck Neoplasms 10Ovarian Neoplasms 8Colorectal Neoplasms 8Recurrence 7Adenocarcinoma, Bronchiolo-Alveolar 7Small Cell Lung Carcinoma 6NSCLC 6Adenocarcinoma 6Parkinson Disease 4, Autosomal Dominant Lewy Body 5Meningeal Carcinomatosis 5Carcinoma 5Urinary Bladder Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Solitary Fibrous Tumor, Pleural 4Sarcoma 4Pancreatic Neoplasms 4Non-small Cell Lung Cancer Metastatic 4Laryngeal Diseases 4Carcinoma, Transitional Cell 4Uterine Neoplasms 3Uterine Cervical Neoplasms 3

Interventions

Carboplatin 7Pemetrexed 6osimertinib 5Drug Therapy 5tislelizumab 3anlotinib 3aflutinib 3Radiotherapy 3Radiosurgery 3Paclitaxel 3Cisplatin 3toripalimab 2pembrolizumab 2camrelizumab 2apatinib 2Surgical Procedures, Operative 2S 1 (combination) 2HM781-36B 2Chemotherapy, Adjuvant 2Chemoradiotherapy 2trilaciclib 1surufatinib 1sintilimab 1rezivertinib 1lenvatinib 1icotinib 1famitinib 1envafolimab 1dacomitinib 1cemiplimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 2 × NSCLC × Pemetrexed × Clear all
NCT07181499 2025-09-30

Sequential Chemotherapy With Befotertinib in Non-Small Cell Lung Cancer (NSCLC) Patients With Resistance to Third-Generation EGFR-TKI

Betta Pharmaceuticals Co., Ltd.

Phase 2 Recruiting
28 enrolled
Thoracic

NSCLC

NCT06944470 2025-04-25

JS207 Combined With Chemotherapy in Subjects With Stage II-III NSCLC

Shanghai Junshi Bioscience Co., Ltd.

Phase 2 Not yet recruiting
76 enrolled
Thoracic

NSCLC

NCT06746870 2024-12-24

A Phase II Clinical Study to Evaluate the Safety, Pharmacokinetic Profile, and Preliminary Efficacy of IMM2510 in Combination with Chemotherapy As First-line Treatment in Subjects with Non-small Cell Lung Cancer or Triple-negative Breast Cancer

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Phase 2 Not yet recruiting
148 enrolled
BreastThoracic

NSCLC

NCT06332287 2024-03-27

A Study of Trilaciclib Combined With Chemotherapy in the Treatment of Advanced NSCLC With Leptomeningeal Metastasis

Jiangsu Province Nanjing Brain Hospital

Phase 2 Unknown
25 enrolled
Thoracic

NSCLC

NCT00754364 2022-09-10

Mono Versus Polichemotherapy in Non Small Cell Lung Cancer (NSCLC) Elderly Patients

Istituto Clinico Humanitas

Phase 2 Terminated
108 enrolled
Thoracic

NSCLC

NCT02631460 2015-12-16

S1 vs.Pemetrexed Plus Carboplatin in Patients With EGFR Wild Type Stage IIIB or IV Nonsquamous NSCLC

Sun Yat-sen University

Phase 2 Unknown
470 enrolled
Thoracic

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡